Objective:

To evaluate the predictive values of nutritional and inflammatory biomarkers for short-term pathological response and long-term survival in patients with locally advanced gastric cancer undergoing neoadjuvant immunotherapy.

Approach:

Key Findings:

• Patients with pCR had significantly better overall survival (OS) and disease-free survival (DFS) compared to those without pCR (P < 0.01).
• pCR group showed a significant decrease in SII levels and increases in PNI and CCR (all P < 0.05).
• Low SII and high PNI and CCR levels correlated with longer OS and DFS (all P < 0.0001).
• A prediction model combining PNI, SII, CCR, and CA199 enhanced the predictive ability of pCR (AUC = 0.917).

Interpretation:

Nutritional and inflammatory biomarkers (SII, PNI, CCR) and CA199 are sensitive markers for immediate pathological response, while SII, PNI, and CA125 are more indicative of long-term prognosis.

Limitations:

• The study was conducted at a single institution, which may limit generalizability.
• The sample size may not be sufficient to capture all variations in patient responses.

Conclusion:

Integrating distinct biomarkers into predictive models can facilitate precise risk stratification and personalized management for patients undergoing neoadjuvant immunotherapy.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.